Inventor
Robert Scott Pearsall
Inventor
North Reading, MA, US
Overview
Patents· 26 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations26%
C07KPeptides26%
A61KPreparations for medical, dental or toiletry purposes25%
C12NMicroorganisms or enzymes9%
C12YEnzymes9%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms4%
PatentTitleYear
11,028,145ALK7:actriib heteromultimers and uses thereof202111,028,374Methods for treating anemia in a subject in need thereof202111,028,375Methods for treating anemia in a subject in need thereof202110,906,958TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof202110,889,626Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels202110,829,533Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels202010,829,532Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels202010,738,098ALK4:ActRIIB heteromultimers and uses thereof202010,689,427Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels202010,377,996Methods of identifying ActRIIB variants201910,227,392ALK7:ActRIIB heteromultimers and uses thereof201910,227,393TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof201910,196,434ALK4:ActRIIB heteromultimers and uses thereof201910,131,700Methods for treating refractory anemia with ringed sideroblasts201810,059,756Compositions comprising ALK1-ECD protein20189,932,379Isolated nucleotide sequences encoding GDF traps20189,505,813'Use of GDF traps to treat anemia'20169,452,197'Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof'20169,439,945'Isolated nucleotide sequences encoding GDF traps'20168,703,927'Isolated nucleotide sequences encoding GDF traps'20148,642,031'Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof'20148,455,428'ALK1 receptor and ligand antagonist and uses thereof'20138,361,957'Isolated GDF trap polypeptide'20138,216,997'Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators'20128,158,584'Pharmaceutical preparations comprising an ALK1-Fc fusion protein'20128,058,229'Method of increasing red blood cell levels or treating anemia in a patient'2011Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2011–2021Patents assigned to ACCELERON PHARMA INC (24)· patent assignee history
2011–2018Patents assigned to KUMAR RAVINDRA (8)· patent assignee history
2011–2018Patents assigned to SEEHRA JASBIR (8)· patent assignee history
2011–2021Based in Woburn, MA, US· patent location history
2012–2018Patents assigned to GRINBERG ASYA (4)· patent assignee history
2012–2018Patents assigned to KNOPF JOHN (4)· patent assignee history
2016–2021Based in North Reading, MA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ACCELERON PHARMA INC | 24 | 2011–2021 |
| KUMAR RAVINDRA | 8 | 2011–2018 |
| SEEHRA JASBIR | 8 | 2011–2018 |
| GRINBERG ASYA | 4 | 2012–2018 |
| KNOPF JOHN | 4 | 2012–2018 |
Locations
| Location | Patents | Span |
|---|---|---|
| North Reading, Massachusetts, US | 13 | 2016–2021 |
| Woburn, Massachusetts, US | 13 | 2011–2021 |